Blood Cancer

Follicular Lymphoma:
Know your options

Lymphoma is the most common type of blood cancer.

Every person’s experience of diagnosis and treatment of lymphoma will be different.

There will be different challenges to navigate, different concerns to deal with, and different questions depending on your unique life circumstances. However, we hope to help you find some answers about your treatment options. Whatever your experience has been so far, knowing you’re getting the best possible treatment available can help you weather the emotional storm of a lymphoma diagnosis.

Roche offer several treatments for lymphoma that are not funded by PHARMAC, but have proven effectiveness in clinical trials. It is possible one of them might be right for you.

Ask your doctor if these treatments are right for you.

Types of lymphoma 

There are two main categories of lymphoma: Hodgkin’s lymphoma and non-Hodgkin’s lymphoma. There are also many different subtypes within each category.

Follicular lymphoma (FL) is a subtype of non-Hodgkin’s lymphoma that develops in B cells (a type of lymphocyte). It’s the most common type of slow growing (indolent) lymphoma, and mainly develops in men and women aged over 60 years.

When someone has FL, abnormal B cells can accumulate in the lymph nodes and bone marrow, as well as in other organs such as the spleen and liver. These abnormal B cells do not function properly, and cannot carry out the normal disease-fighting functions of white blood cells. As they grow in number, they crowd out healthy blood cells and it’s hard for your body to fight off infections.

Roche follicular lymphoma treatments available in New Zealand

Gazyva® (obinutuzumab)

Gazyva is a monoclonal antibody therapy, used for the treatment of indolent non- Hodgkin’s lymphoma (iNHL).

MabThera® (rituximab)

MabThera is a monoclonal antibody therapy for the treatment of indolent non-Hodgkin’s lymphoma (iNHL).